干旱区生态环境知识资源中心(Arid): Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma

Arid

DOI	10.1016/j.clgc.2021.07.010
	Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma
	Sorokina, Maria; Stupichev, Danil; Lyu, Yang; Ramachandran, Akshaya; Miheecheva, Natalia; Brown, Jessica H.; Nomie, Krystle; Postovalova, Ekaterina; Bagaev, Alexander; Tsiper, Maria; Hsieh, James J.
通讯作者	Hsieh, JJ (corresponding author), Washington Univ Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA.
来源期刊	CLINICAL GENITOURINARY CANCER
ISSN	1558-7673
EISSN	1938-0682
出版年	2021
卷号	19 期号:6 页码:E374-E381
英文摘要	This study was designed to determine the ability of RNA-Seq to detect PD-L1 expression in comparison with IHC in clear cell renal cell carcinoma (ccRCC). Analysis of 127 ccRCC clinical samples demonstrated that RNASeq can detect PD-L1 expression as accurately as IHC. These results suggest that PD-L1 detection by RNA-Seq can be further developed for clinical utility in ccRCC. Background: Although there are immune checkpoint inhibitors (ICIs) available for the treatment of renal cell carcinoma (RCC), the utility of PD-L1 detection by immunohistochemistry (IHC) as a predictive biomarker in clear cell RCC (ccRCC) remains controversial. Nevertheless, alternative methods for PD-L1 detection, such as RNA sequencing (RNASeq), may be clinically useful in ccRCC; therefore, we sought to determine the ability of RNA-Seq to accurately and sensitively detect PD-L1 expression across different ccRCC clinical samples in comparison with IHC. Patients and Methods: Patients with ccRCC (n=127) who received treatment from Washington University in St. Louis between 2018 and 2020 were identified. Tumors from these patients were analyzed using RNA-Seq and IHC. Results: PD-L1 detection by RNA-Seq strongly correlated with IHC (P <.001), which was further validated using two independent datasets. Furthermore, RNA-Seq analysis identified an immune-enriched (higher PD-L1 positivity) and an immune-desert (lower PD-L1 positivity) microenvironment of ccRCC, which also correlated with IHC (P <.00001). Conclusion: The results demonstrate the ability of RNA-Seq to detect PD-L1 in various ccRCC clinical samples compared to IHC. Ultimately, these findings suggest that PD-L1 detection by RNA-Seq can be further developed to determine the clinical utility of this methodology in ccRCC. (C) 2021 Published by Elsevier Inc.
英文关键词	Immunohistochemistry Tumor microenvironment Programmed death ligand 1 RNA-Sequencing Clear Cell Renal Cell Carcinoma
类型	Article
语种	英语
收录类别	SCI-E
WOS记录号	WOS:000731363100006
WOS类目	Oncology ; Urology & Nephrology
WOS研究方向	Oncology ; Urology & Nephrology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/373969
作者单位	[Sorokina, Maria; Stupichev, Danil; Miheecheva, Natalia; Brown, Jessica H.; Nomie, Krystle; Postovalova, Ekaterina; Bagaev, Alexander; Tsiper, Maria] BostonGene Corp, Waltham, MA USA; [Lyu, Yang; Ramachandran, Akshaya; Hsieh, James J.] Washington Univ Sch Med, Div Oncol, Dept Med, St Louis, MO USA
推荐引用方式 GB/T 7714	Sorokina, Maria,Stupichev, Danil,Lyu, Yang,et al. Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma[J],2021,19(6):E374-E381.
APA	Sorokina, Maria.,Stupichev, Danil.,Lyu, Yang.,Ramachandran, Akshaya.,Miheecheva, Natalia.,...&Hsieh, James J..(2021).Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma.CLINICAL GENITOURINARY CANCER,19(6),E374-E381.
MLA	Sorokina, Maria,et al."Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma".CLINICAL GENITOURINARY CANCER 19.6(2021):E374-E381.